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Introduction: Children admitted to a pediatric intensive care unit (ICU) are at high risk of developing acute kidney
injury (AKI). Although serum creatinine (SCr) levels are used in clinical practice, they are insensitive for early diagnosis
of AKI. Urinary neutrophil gelatinase-associated lipocalin (uNGAL) and kidney injury molecule-1 (KIM-1) are novel AKI
biomarkers whose performance in pediatric ICU patients is largely unknown. In this study, we aimed to characterize
uNGAL and KIM-1 patterns in children following ICU admission and to assess their properties in relation to identifying
children at risk for AKI development.
Methods: From June 2010 until January 2014, we conducted a prospective observational cohort study of term-born
children ages 1 day to 1 year on mechanical ventilation. Blood and urine samples were obtained every 6 to 12 hours
up to 72 hours post-admission. Blood samples were assayed for SCr, and urine samples were assayed for uNGAL and
KIM-1. The RIFLE (risk, injury, failure, loss, end-stage renal disease) classification as 150%, 200% or 300% of median SCr
reference values was used to define AKI.
Results: A total of 100 children were included (80 survived). Their median age at admission was 27.7 days (interquartile
range (IQR), 1.5 to 85.5). The median duration of mechanical ventilation was 5.8 days (IQR, 3.1 to 11.4). Thirty-five patients
had evidence of AKI within the first 48 hours post-admission, of whom 24 (69%) already had AKI when they
entered the ICU. uNGAL and KIM-1 concentrations in AKI peaked between 6 to 12 hours and between 12 to 24 hours
post-admission, respectively. The maximal area under the receiver operating characteristic curve (AUC) for uNGAL
was 0.815 (95% confidence interval (CI), 0.685 to 0.945, P <0.001) at 0 to 6 hours post-admission. The discriminative
ability of KIM-1 was moderate, with a largest AUC of 0.737 (95% CI, 0.628 to 0.847; P <0.001) at 12 to 24 hours
post-admission. At the optimal cutoff point (126 ng/ml), uNGAL concentration predicted AKI development correctly
in 16 (84%) of 19 children, up to 24 hours before a rise in SCr became apparent.
Conclusions: Levels of uNGAL and KIM-1 increase in patients with AKI following ICU admission and peak at 6 to
12 hours and 12 to 24 hours post-admission, respectively. uNGAL seems to be a reliable marker for identifying children
who will develop AKI 24 hours later.* Correspondence: a.zwiers@erasmusmc.nl
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Acute kidney injury (AKI) is a frequent and serious com-
plication in critically ill children [1-7]. Moreover, it has
been shown to be an independent risk factor for mortal-
ity, prolonged length of intensive care unit (ICU) stay
and prolonged mechanical ventilation [1,2,5]. Current
consensus criteria for diagnosing AKI are based on
changes in serum creatinine (SCr) and urine output
[4,8]. One must realize, however, that SCr is an indicator
of glomerular function rather than renal tubular cell
damage, which typically occurs during the initial phase
of AKI in ICU patients [9,10]. In addition, a substantial
number of functioning nephrons have to be compro-
mised before changes in SCr levels become evident [11].
Moreover, SCr is influenced by factors unrelated to renal
function and in the newborn reflects maternal levels
immediately after birth [11,12]. Altogether, SCr is in-
creasingly considered a late and not very sensitive
marker for diagnosing AKI.
Therefore, research has increasingly focused on the
identification of novel, more sensitive biomarkers for
renal injury, especially tubular, injury, including urinary
neutrophil gelatinase-associated lipocalin (uNGAL) and
kidney injury molecule-1 (KIM-1) [13]. NGAL is a small,
25 kDa protein initially discovered in activated human
neutrophils [14]. NGAL is expressed in limited quan-
tities in other human tissues, including the lungs, spleen
and kidneys, where it is thought to inhibit bacterial
growth, scavenge iron and induce epithelial growth
[14-18]. Plasma NGAL is freely filtered by the glomeru-
lus and then largely reabsorbed by proximal tubular cells
[19]. Upon renal tubular injury, NGAL reabsorption may
be decreased, whereas NGAL de novo synthesis in epi-
thelial cells of the loop of Henle and of distal tubule
segments is strongly upregulated, after which it is found
in high concentrations in the urine [20]. KIM-1 is a
104 kDa type I transmembrane glycoprotein that con-
tains both an immunoglobulin-like domain and a mucin
domain in its extracellular portion [21]. It is expressed
in low levels in healthy proximal tubule cells and is
thought to promote apoptotic and necrotic cell clearance
[22]. Upon kidney ischemia or toxicity, KIM-1 is highly
upregulated and shed into the extracellular space and
urine [21,22].
The usefulness of uNGAL was first recognized by
Mishra and colleagues, who demonstrated that postoper-
ative uNGAL levels in children at 2 hours after cardio-
pulmonary bypass (CPB) had a nearly 100% accuracy for
predicting AKI at 24 to 72 hours [23]. Subsequent stud-
ies, mainly in adults, in clinical settings such as critical
care and kidney transplantation confirmed this finding
[24,25]. KIM-1, on the other hand, has been systematic-
ally investigated only in patients undergoing CPB and
in a small sample of asphyxiated neonates [26,27].Zappitelli and colleagues [28] were the first to evaluate
uNGAL in a large, heterogeneous group of pediatric ICU
(PICU) patients. They found a good diagnostic marker
for development of AKI and persistent AKI for ≥48 hours,
but not for AKI if uNGAL had been measured after a rise
in SCr [28]. In later studies focused on cutoff points for
AKI prediction specifically in PICU patients, researchers
evaluated biomarker combinations and even suggested
uNGAL as a predictor of mortality [29,30].
None of these previous studies, however, provided
insight into biomarker evolution using time intervals
based on the hours shortly after ICU admission. Besides,
for these studies, authors reported data for subjects with
age ranges widely varying from 1 week to 21 years
[27-31]. None focused on children up to 1 year of age,
even though this age group is particularly vulnerable to
renal injury during the physiological evolution of renal
function. Therefore, our aim in the present study was to
characterize temporary uNGAL and KIM-1 patterns in
the 3 days following ICU admission in a large cohort of
critically ill children up to 1 year of age. Secondarily, we
aimed to assess whether the levels of these biomarkers
during the first 24 hours of PICU admission can reliably
identify children at risk for AKI development within
48 hours following admission.
Material and methods
Setting
From June 2010 until January 2014, a single-center pro-
spective observational cohort study was conducted in
the level III ICU of the Erasmus Medical Center–Sophia
Children’s Hospital, Rotterdam, the Netherlands. Con-
sidered for enrollment were children (born later than
37 weeks of gestational age) between the ages of 1 day
and 1 year admitted to the ICU and requiring endo-
tracheal intubation and mechanical ventilation. Patients
were not eligible for inclusion if (1) they had congenital
abnormalities of the kidney or urinary tract, (2) death
was anticipated within 24 hours or (3) they received
mechanical ventilation for other reasons (for example,
neuromuscular disease). Patients were excluded when
treatment with extracorporeal membrane oxygenation was
required within the study period. The study protocol was
approved by the local medical ethics review board of the
Erasmus Medical Center. A deferred consent process was
used whereby written informed consent was obtained from
the primary caregivers within 12 hours following the study
start. The collected blood and urine specimens of those
children for whom consent was withdrawn were destroyed
(n = 10 children, maximum of 1.4 ml of blood per patient).
Sample collection and analytical procedures
Upon ICU admission, blood and urine samples were
prospectively collected concurrently during the patient’s
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(T1), 12 and 24 hours (T2), 24 and 36 hours (T3), 36
and 48 hours (T4) and 48 and 72 hours (T5). For each
time frame, 0.7 ml of blood was drawn with an indwell-
ing arterial line, if available, or by capillary or venous
puncture. Urine samples were collected using a bladder
catheter. To collect 3 ml of freshly voided urine, the
urine collection bag was emptied 1 hour prior to each
sampling time frame. Urine samples were left refriger-
ated for sedimentation for 2 to 3 hours, aliquoted and
stored within 4 hours after collection at −80°C until per-
forming the assay.
Creatinine concentrations were measured in the hospi-
tal’s clinical chemical laboratory by using an enzymatic
assay (Creatinine Plus; Roche Diagnostics, Branchburg,
NJ, USA) on a cobas 8000 analyzer (Roche Diagnostics).
During the period of sample collection, the interassay
coefficient of variation (CV) was less than 2.6%.
uNGAL was measured using the latest uNGAL chemi-
luminescence microparticle immunoassay developed for
a standardized clinical platform (ARCHITECT immuno-
assay analyzer; Abbott Diagnostics Division, Abbott
Laboratories, Abbott Park, IL, USA). The mean interas-
say CV for uNGAL was 5.3% at a concentration of
19.4 ng/ml. The limit of quantification (LoQ) of uNGAL
was 3.0 ng/ml, and the upper limit of quantitation was
6,000 ng/ml. The reagents and calibrator for the uNGAL
assays were kindly supplied by Abbott Diagnostics.
KIM-1 was measured using a commercially available
enzyme-linked immunosorbent assay kit (BioAssay
Works, Ijamsville, MD, USA). The mean interassay
CV for KIM-1 was <14% at a concentration of 0.17 ng/ml.
The LoQ of KIM-1 was 0.08 ng/ml. uNGAL and KIM-1
levels are expressed in absolute values (nanograms
per milliliter).
Data collection
Recorded patient data included clinical characteristics
and results of laboratory tests. More specifically, sex,
gestational age and birth weight, as well as age, body
weight and diagnosis at admission, were collected. The
Pediatric Risk of Mortality II (PRISM II) score and
Pediatric Index of Mortality 2 score were collected as an
indication of severity of illness [32,33]. Furthermore, car-
diac arrest upon ICU admission and type of mechanical
ventilation were registered, together with the fraction of
inspired oxygen at the time of intubation, the need for
nitric oxide ventilation, and the administration of vaso-
pressor drugs, diuretics (furosemide or bumetanide) or
aminoglycosides (gentamicin, tobramycin or amikacin).
Last, data on the following outcomes were collected:
treatment with renal replacement therapy, duration of
mechanical ventilation, lengths of ICU and hospital stay
and survival until ICU discharge.Definitions
AKI was defined according to the maximal SCr-based
RIFLE (risk (R), injury (I), failure (F), loss, end-stage
renal disease) score obtained within the first 48 hours
following admission. The RIFLE classifications we used
defined three grades of increasing AKI severity, includ-
ing R (risk for kidney injury), I (injury to the kidney) and
F (failure of kidney function) [8]. RIFLE outcome cat-
egories L (loss of renal function) and E (end-stage renal
disease) were not applicable, as the study was restricted
to the first 7 days following ICU admission. Because all
children enrolled were younger than 1 year of age, most
did not have data available for baseline SCr concentra-
tions pre-ICU admission, nor is there an algorithm avail-
able to calculate estimated glomerular filtration rate,
which is why the RIFLE categories risk, injury and fail-
ure were defined as SCr concentrations above 150%,
200% and 300%, respectively, of the median age-specific
SCr reference value. These SCr reference values were
obtained from a large cohort of children without kidney
disease by using short age intervals ranging from 1 day
in the first week after birth up to 3 months at the end of
the first year of age [34]. Persistent AKI was defined as
lack of improvement of RIFLE score within 72 hours
post-admission.
Statistical analysis
Unless indicated otherwise, continuous data are ex-
pressed as median values with interquartile ranges
(IQRs) and discrete data as numbers with percentages.
Patients were grouped according to whether they lacked
AKI or had AKI (based on RIFLE score for risk, injury
and/or failure) within 48 hours following admission.
Clinical characteristics and biomarker levels were com-
pared between AKI and non-AKI patients using univari-
ate analyses for continuous variables (Mann–Whitney U
test) and categorical variables (Pearson’s χ2 test or
Fisher’s exact test, as appropriate). Biomarker levels were
also compared between RIFLE strata and diagnostic cat-
egories using univariate overall comparisons between
groups (Kruskal-Wallis test). Receiver operating charac-
teristic (ROC) curves were generated for the occurrence
of AKI within 48 hours following intubation using bio-
marker levels within three different time frames (T0, T1
and T2: 0 to 6 hours, 6 to 12 hours and 12 to 24 hours,
respectively) as well as 24-hour peak levels. The areas
under the ROC curve (AUCs) with 95% confidence in-
tervals (95% CI) were calculated. Also, for each time
frame, the optimal cutoff value based on the Youden
index was calculated with corresponding sensitivity and
specificity. Using those cutoff values, sensitivity and spe-
cificity of both biomarkers for predicting AKI, as well as
the positive and negative predictive values, were calcu-
lated for patients who developed AKI later within the
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sidered AKI-free upon admission. Of these patients, the
timing and absolute values of maximum biomarker
levels in urine samples preceding AKI were compared
with biomarker levels in the first urine samples of con-
trols (critically ill children who did not have AKI). A
two-sided P-value of 0.05 was considered the limit of
significance in all analyses. Data were analyzed using




A total of 110 patients were initially included by deferred
consent. However, because consent was withdrawn by
10 (9%) parents, 100 patients were ultimately enrolled in
the study. Table 1 details the characteristics of all pa-
tients stratified by occurrence of AKI within 48 hours
post-admission. At admission, median age was 27.7 days
(IQR, 1.5 to 85.5), and median body weight was 3.8 kg
(IQR, 3.2 to 5.3). The most common primary diagnoses
were congenital diaphragmatic hernia (n = 23 (23%)) and
respiratory failure (n = 20 (20%)). For all patients, the
median duration of mechanical ventilation was 5.8 days
(IQR, 3.1 to 11.4), and the median ICU stay was
10.0 days (IQR, 6.1 to 27.0). Seventeen patients (17%)
died during admission after a median ICU stay of
11.7 days (IQR, 4.4 to 27.2).
Acute kidney injury
Thirty-five patients (35%) met the criteria for AKI within
48 hours following ICU admission. Fifteen (42%) of
those were classified as RIFLE-R, 10 (29%) as RIFLE-I
and 10 (29%) as RIFLE-F. One patient classified as
RIFLE-F received renal replacement therapy starting
2 days post-admission. Twenty-four (69%) of the thirty-
five patients with AKI already met the criteria for AKI at
the time of admission (risk: n = 6 (25%); injury: n = 8
(33%); failure: n = 10 (42%)).
Age, weight, diagnosis and cardiac arrest experienced
upon ICU admission did not significantly differ between
patients who developed AKI within 48 hours following
admission and those who did not (Table 1). Nonetheless,
patients in the former group were more severely ill on
admission, as reflected by a significantly higher PRISM
II score (48.9 (IQR, 25.5 to 77.1)) than that assigned to
non-AKI patients (25.1 (IQR, 10.10 to 54.1) (P <0.001 by
Mann–Whitney U test). Moreover, patients with AKI
were ventilated almost twice as long as non-AKI pa-
tients, although type of mechanical ventilation, fraction
of inspired oxygen and need for nitric oxide ventilation
did not differ. Patients with AKI more often received
two or more types of vasopressor drugs at intubation
and had longer ICU and hospital lengths of stay. Incontrast, there was no difference in the prescription of
diuretic drugs and aminoglycosides between AKI and
non-AKI patients. Last, the overall mortality rate in
patients with AKI was significantly higher than that
of non-AKI patients (32% versus 14%; P = 0.027 by
Pearson’s χ2 test).
Biomarker patterns post-admission
In total, 491 urine samples were collected (that is, 86%
of all scheduled samples (5 samples (IQR, 4 to 5) per
patient). Sampling was not feasible in cases of anuria,
discontinuation of bladder catheterization or logis-
tical problems. The median uNGAL concentration
for all urine specimens was 39.5 ng/ml (IQR, 12.4 to
168.1 ng/ml) and the median KIM-1 concentration
was 0.14 ng/ml (IQR, 0.08 to 0.30 ng/ml). For pa-
tients with AKI, the median uNGAL and KIM-1 con-
centrations were 107 ng/ml (IQR, 22.4 to 935) and
0.19 ng/ml (IQR, 0.10 to 0.43), respectively, which were
significantly higher than those for non-AKI patients:
uNGAL of 23.2 ng/ml (IQR, 9.6 to 93) and KIM-1 of
0.13 ng/ml (IQR, 0.08 to 0.25) (both P-values <0.001 by
Mann–Whitney U test).
Figure 1 presents the patterns of median uNGAL and
KIM-1 levels from 0 to 72 hours following ICU admis-
sion. Both patterns showed an increase; the mean
uNGAL concentration peaked at 6 to 12 hours, and
the mean KIM-1 concentration peaked at 12 to
24 hours. uNGAL levels were significantly higher in
the patients who developed AKI than in the non-AKI
patients at all time frames except for T6 (48 to
72 hours) (all P-values ≤0.038 by Mann–Whitney U test).
KIM-1 levels were significantly higher in patients with
AKI only at T2 (12 to 24 hours) and T3 (24 to 36 hours)
(both P-values ≤0.041 by Mann–Whitney U test). Table 2
shows the uNGAL and KIM-1 concentrations for T0
(0 to 6 hours), T1 (6 to 12 hours) and T2 (12 to
24 hours) and the peak levels within 24 hours by SCr-
based RIFLE strata. Worse RIFLE status was significantly
associated with higher uNGAL and KIM-1 levels (all
P-values ≤0.018 by Kruskal-Wallis test). Compared across
diagnostic categories, uNGAL and KIM-1 concentrations
were both highest in patients with sepsis, especially those
who met the AKI criteria (both P-values <0.001 by
Kruskal-Wallis test) (Figure 2).
Urinary neutrophil gelatinase-associated lipocalin, kidney
injury molecule-1 and mortality
Seventeen patients died during admission. Three of
these non-survivors died within the first 72 hours, of
whom one was classified in the non-AKI group (died
after 66 hours, peak uNGAL value of 114 ng/ml) and
two were in the AKI-group (died after 46 and
54 hours, respectively, both with peak uNGAL values
Table 1 Patient characteristics grouped according to occurrence of acute kidney injurya
All patients (n = 100) Non-AKI (n = 65) AKI (n = 35) P-valueb
Baseline characteristics
Male sex 66 (66) 42 (65) 24 (69) 0.690c
Gestational age, wk 39.0 (37.6 to 40.0) 38.9 (37.8 to 40.0) 39.0 (37.4 to 40.0) 0.861d
Birth weight, kg 3.1 (2.8 to 3.6) 3.1 (2.8 to 3.5) 3.1 (2.8 to 3.6) 0.989d
Clinical characteristics at intubation
Age, days 27.7 (1.5 to 85.5) 27.1 (1.8 to 71.4) 30.3 (1.4 to 115.0) 0.667d
Weight, kg 3.8 (3.2 to 5.2) 3.7 (3.3 to 5.0) 3.8 (3.1- 6.0) 0.745d
Admission diagnosis
Congenital diaphragmatic hernia 23 (23) 16 (25) 7 (20) 0.132c
Respiratory failure 20 (20) 11 (17) 9 (26)
Cardiac failure 18 (18) 8 (12) 10 (28)
RSV bronchiolitis 17 (17) 14 (21) 3 (9)
Sepsis 14 (14) 9 (14) 5 (14)
Other 8 (8) 7 (11) 1 (3)
Cardiac arrest on ICU admission, yes 10 (10) 5 (8) 5 (14) 0.283c
Severity of illness at ICU admission
PIM2, % 9.8 (3.4 to 18.8) 7.0 (1.7 to 12.0) 15.9 (8.4 to 38.1) 0.011d
PRISM II, % 33.8 (11.0 to 64.5) 25.7 (10.1 to 54.1) 48.9 (25.5 to 77.1) <0.001d
Type of mechanical ventilation
Pressure control 68 (68) 45 (69) 23 (66) 0.671c
Pressure-regulated volume control 19 (19) 11 (17) 8 (23)
High-frequency ventilation 11 (11) 7 (11) 4 (11)
Pressure support 2 (2) 2 (3) –
Fraction of inspired oxygen at intubation, percentage 59 (40 to 94) 55 (40 to 90) 68 (39 to 100) 0.422d
Need for nitric oxide ventilation at intubation, yes 18 (18) 10 (15) 8 (23) 0.354c
Need for two or more vasopressors at intubation, yes 49 (49) 24 (37) 25 (71) 0.001c
Diuretic drugs, yes 77 (76) 46 (71) 30 (86) 0.095d
Aminoglycosides, yes 37 (37) 24 (36) 13 (37) 0.983d
Outcomes
Need for renal replacement therapy, yes 1 (1) – 1 (3) N/A
Duration of mechanical ventilation, days 5.8 (3.1 to 11.4) 4.4 (3.0 to 8.3) 8.3 (5.6 to 19.1) 0.001d
Length of ICU stay, days 10.0 (6.1 to 27.0) 8.3 (5.8 to 15.9) 19.2 (7.8 to 35.6) 0.002d
Length of hospital stay, days 15.9 (8.1 to 38.0) 11.6 (6.5 to 27.9) 27.0 (11.1 to 46.9) 0.015d
Mortality 20 (20) 9 (14) 11 (32) 0.027c
ICU 17 7 10 N/A
Time from admission until death, days 11.7 (4.4 to 27.2) 9.9 (3.4 to 17.0) 18.7 (6.7 to 45.0) N/A
aAKI, Acute kidney injury; ICU, Intensive care unit; N/A, Not applicable; PIM2, Pediatric Index of Mortality 2; PRISM II, Pediatric Risk of Mortality II; RSV, Respiratory
syncytial virus. Patient demographic data and clinical characteristics of all patients enrolled, grouped according to the development of AKI (yes or no), are shown.
AKI was defined according to the highest RIFLE (risk, injury, failure, loss, end-stage renal disease) score attained within 48 hours following admission. The RIFLE
categories risk, injury and failure were defined as, respectively, serum creatinine (SCr) above 150%, 200% and 300% of the median age-specific SCr reference
values. Continuous data are expressed as median (interquartile range), and categorical data are expressed as number (%). bP-values indicate comparison between
AKI and non-AKI patients using univariate analyses. cPearson’s χ2 test or Fisher’s exact test, as appropriate, for categorical variables. dMann–Whitney U test for
continuous variables.
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24 hours post-admission, as well as their 24-hour peak
levels, were higher than those of survivors (P-values ≤0.009by Mann–Whitney U test). There was no significant differ-
ence between survivors and non-survivors with regard to
KIM-1 levels (all P-values >0.05).
Figure 1 Clinical course of mean urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 levels from 0 to 72 hours following
intubation, stratified by occurrence of acute kidney injury within 48 hours post-admission. Data represent the mean (±1 standard error of the mean).
The filled diamonds represent patients with acute kidney injury (AKI), and the open circles represent non-AKI patients. Differences were assessed for
each biomarker per time frame using Mann–Whitney U tests. KIM-1, Kidney injury molecule-1; uNGAL, Urinary neutrophil gelatinase-associated lipocalin.
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curve analysis
Table 3 shows the AUCs for the prediction of the devel-
opment of AKI within 48 hours following admission for
both biomarkers at T0, T1 and T2, as well as for 24-
hour peak levels. The maximal AUC for uNGAL was
0.815 (95% CI, 0.685 to 0.945; P-value <0.001) at T0
(0 to 6 hours), with an optimal cutoff value of
126 ng/ml with a sensitivity of 76% and a specificity
of 84%. The AUCs for uNGAL were 0.780 (95% CI,
0.678 to 0.882; P-value <0.001) at T1, 0.711 (95% CI,
0.599 to 0.824; P-value =0.001) at T2 and 0.811 (95% CI,
0.719 to 0.902; P-value <0.001) for the 24-hour peak levels.
KIM-1 was moderately discriminative only at T2, with anAUC of 0.737 (95% CI, 0.628 to 0.847; P-value <0.001) and
an optimal cutoff value of 0.19 ng/ml with a sensitivity of
72% and specificity of 67%. Figure 3 shows the ROC curve
of uNGAL and KIM-1 levels at T0, T1 and T2 and for the
24-hour peak levels.
Urinary neutrophil gelatinase-associated lipocalin and
kidney injury molecule-1 concentrations preceding acute
kidney injury
Twenty-four patients already met the AKI criteria at the
time of ICU admission, and nineteen other patients de-
veloped AKI later within the 72-hour admission (eleven
within 48 hours and another eight between 48 and
72 hours post-admission). These 19 patients reached
Table 2 T0, T1, T2 and peak urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 concentrations
by serum creatinine-based RIFLE status within 48 hours following admissiona
Measurement, number of patients Non-AKI, n = 65 RIFLE-Risk, n = 15 RIFLE-Injury, n = 10 RIFLE-Failure, n = 10 P-value
T0, 0 to 6 hr
uNGAL (ng/ml), n = 59 31 (16 to 111) 396 (70to 1,250) 385 (77 to 1,987) 1,873 (484 to 3,936) <0.001
KIM-1 (ng/ml), n = 59 0.11 (0.08 to 0.19) 0.18 (0.13 to 0.28) 0.10 (0.08 to 0.11) 1.2 (0.4 to 3.5) 0.004
T1, 6 to 12 hr
uNGAL (ng/ml), n = 85 21 (8 to 116) 114 (61 to 420) 275 (11 to 4630) 2430 (727 to 6000) <0.001
KIM-1 (ng/ml), n = 85 0.11 (0.08 to 0.27) 0.10 (0.08 to 0.29) 0.12 (0.08 to 0.16) 0.35 (0.29 to 1.21) 0.018
T2, 12 to 24 hr
uNGAL (ng/ml), n = 95 22 (10 to 98) 34 (22 to 200) 47 (26 to 1935) 979 (301 to 6000) 0.001
KIM-1 (ng/ml), n = 93 0.16 (0.08 to 0.28) 0.26 (0.11 to 0.56) 0.30 (0.12 to 0.41) 0.47 (0.26 to 2.15) 0.002
24-hr peak level
uNGAL (ng/ml), n = 100 59 (16 to 136) 225 (89 to 730) 385 (56 to 3938) 1495 (387 to 6000) <0.001
KIM-1 (ng/ml), n = 100 0.17 (0.08 to 0.34) 0.26 (0.11 to 0.56) 0.25 (0.10 to 0.41) 0.86 (0.44 to 2.15) 0.001
aAKI, Acute kidney injury; KIM-1, Kidney injury molecule-1; RIFLE, Risk, injury, failure, loss, end-stage renal disease; SCr, Serum creatinine; uNGAL, Urinary neutrophil
gelatinase-associated lipocalin. Data are expressed as median (interquartile range). P-values indicate overall comparison of all groups (that is, non-AKI versus Risk
versus Injury versus Failure). Intergroup differences were assessed using the Kruskal-Wallis test. RIFLE categories risk, injury and failure were defined as, respectively, serum
creatinine (SCr) above 150%, 200% and 300% of the median age-specific SCr reference values.
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(IQR, 20 to 53) post-admission (Risk: n = 16 (84%);
Injury: n = 3 (16%)). For the analysis of biomarkers
preceding AKI, the time point at which AKI first oc-
curred was recoded to T0. All available uNGAL and
KIM-1 measurements preceding this time point were
recoded relative to T0 (Figure 4). Using the optimal
cutoff value for uNGAL (126 ng/ml) and KIM-1
(0.19 ng/ml) levels as described above, uNGAL was
the most sensitive biomarker for predicting the devel-
opment of AKI (that is, in 16 (84%) of 19 cases using
uNGAL concentration versus 11 (58%) of 19 cases using
KIM-1 concentration).
The maximum biomarker levels in urine samples
preceding AKI (T0) were then used to evaluate the
diagnostic performances of both biomarkers for AKI
prediction. The first urine samples of 49 patients who
did not develop AKI served as controls. The clinical
characteristics and outcomes of these 49 control pa-
tients did not differ from those of the 19 patients with
AKI (all P-values >0.05). Maximum uNGAL and KIM-1
levels were observed at medians of 22 hours (IQR, 12
to 24) and 9 hours (IQR, 5 to 15), respectively, before
reaching RIFLE-Risk level or higher for the first time. A
contingency table analysis using a cutoff value >126 ng/ml
for uNGAL showed that the sensitivity of uNGAL was
84%, its specificity was 86%, its positive predictive value
was 70% and its negative predictive value was 93%
(Figure 5). At a cutoff value of 0.19 ng/ml, the sensi-
tivity of KIM-1 was 58%, its specificity was 78%, its
positive predictive value was 50% and its negative pre-
dictive value was 83%.Persistent acute kidney injury
Of the 24 patients who had AKI upon admission, 13 had
persistent AKI in the time frame between 48 and
72 hours, whereas the RIFLE score improved in 11. Bio-
marker levels did not differ significantly between groups.
Discussion
The aim of this study was to characterize uNGAL and
KIM-1 patterns throughout the first days of ICU admis-
sion in critically ill children requiring mechanical venti-
lation and to assess their properties for identifying
children who develop AKI. We show that levels of both
biomarkers increased following admission and were sig-
nificantly higher with worsening AKI severity. Most im-
portant, we found that uNGAL levels in the first 6 hours
following admission can serve as a marker for identifying
children meeting AKI criteria within 48 hours of ICU
admission. Besides, when using the optimal cutoff
uNGAL value (126 ng/ml), 16 of 19 patients in whom
AKI was detected 24 hours later would have been diag-
nosed correctly. In contrast, KIM-1 was not found to be
reliable in identifying children at risk for AKI. Thus, in a
heterogeneous group of critically ill children, uNGAL
may allow for an early diagnosis of AKI, even before a
rise in SCr becomes apparent.
Of the 35 patients diagnosed with AKI within 48 hours
following admission, a remarkable proportion of almost
70% already had AKI upon admission, including the
most severe cases. These figures are in line with a large
retrospective cohort study in which investigators evalu-
ated 2,106 admissions to the PICU in whom AKI oc-
curred predominantly on the first PICU day [2].
Figure 2 Maximal urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 levels within 24 hours post-admission, stratified
by diagnosis upon admission (total number of patients = 100). Data represent the mean (±1 standard error of the mean). The black-and-white
boxes represent patients with acute kidney injury (AKI), and the gray boxes represent non-AKI patients. Intergroup differences were assessed using
Kruskal-Wallis tests. CDH, Congenital diaphragmatic hernia; KIM-1, Kidney injury molecule-1; RSV, Respiratory syncytial virus; uNGAL, Urinary neutrophil
gelatinase-associated lipocalin.
Table 3 Occurrence of acute kidney injury within 48 hours following intubationa
Biomarker Number of patients (%) Time frame AUC (95% CI) P-value Cutoff (ng/ml) Sensitivity (%) Specificity (%)
uNGAL 59 (59%) T0, 0 to 6 hr 0.815 (0.685 to 0.945) <0.001 126 76 84
85 (85%) T1, 6 to 12 hr 0.780 (0.678 to 0.882) <0.001 88 70 74
95 (95%) T2, 12 to 24 hr 0.711 (0.599 to 0.824) 0.001 32 72 62
100 (100%) 24-hr peak level 0.811 (0.719 to 0.902) <0.001 1,338 80 77
KIM-1 58 (57.4%) T0, 0 to 6 hr 0.618 (0.469 to 0.768) 0.135 0.15 52 60
85 (85%) T1, 6 to 12 hr 0.553 (0.469 to 0.729) 0.135 0.13 55 60
93 (931%) T2, 12 to 24 hr 0.737 (0.628 to 0.847) <0.001 0.19 72 67
100 (100%) 24-hr peak level 0.695 (0.584 to 0.807) 0.001 0.24 71 62
aAUC, Area under the receiver operating characteristic curve; CI, Confidence interval; KIM-1, Kidney injury molecule-1; uNGAL, Urinary neutrophil gelatinase-associated
lipocalin. The optimal cutoff was based on the Youden index.
Zwiers et al. Critical Care  (2015) 19:181 Page 8 of 14
Figure 3 Receiver operating characteristic curves of urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 levels at time
frames T0, T1 and T2 and for the 24-hour peak levels. The dashed black lines represent the receiver operating characteristic (ROC) curves of urinary
neutrophil gelatinase-associated lipocalin (uNGAL), and the dotted lines represent the ROC curves of kidney injury molecule-1 (KIM-1). The gray
lines represent the reference value.
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biomarker levels than reported previously [27,28].
Zappitelli and colleagues reported a median peak uNGAL
level of 55 ng/ml (IQR, 105) for patients with RIFLE-F,
whereas we found a median value of 1,495 ng/ml (IQR,
387 to 6,000) [28]. This is even more surprising in light of
the fact that 23% of patients in the Zappitelli study had
sepsis, compared with only 14% in our study. Our present
study as well as other studies have shown that patientswith sepsis have the highest levels of uNGAL and KIM-1,
irrespective of AKI development, which is at least in part
due to systemic inflammation [25,31,35,36]. Another ex-
planation may lie in the lower severity of illness in the
Zappitelli cohort, as reflected by a median PRISM II score
of 19 (IQR, 12) [28] for the renal failure group compared
with 48.9 (IQR, 25.5 to 77.1) in our patients with AKI.
Furthermore, as uNGAL and KIM-1 levels in premature
infants and young children generally are higher than healthy
Figure 4 Urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 levels prior to the onset of acute kidney injury, defined
as attaining RIFLE-Risk level or higher (n = 19). Data represent the mean (±1 standard error of the mean). Acute kidney injury (AKI) was defined as
a rise in serum creatinine of 150% or greater compared with age-specific reference values, which equals RIFLE-Risk level or higher. KIM-1, Kidney
injury molecule-1; RIFLE, Risk, injury, failure, loss, end-stage renal disease; uNGAL, Urinary neutrophil gelatinase-associated lipocalin.
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might form another explanation [29,37,38]. Last, Zappitelli
and colleagues used other biomarker kits [28].
We have shown that levels of both biomarkers in-
creased following admission, with uNGAL levels peaking
between 6 and 12 hours and KIM-1 levels peaking some-
what later, between 12 and 24 hours. These patterns re-
semble those reported in a well-conducted study of 543
adult ICU patients in which uNGAL levels in patientswith AKI increased starting from the time of admission
(P <0.0001) and KIM-1 levels first differentiated between
non-AKI and AKI patients 24 hours post-admission
(P = 0.008) [39]. To the best of our knowledge, there
are no pediatric studies available on the patterns of
biomarkers following ICU admission using hourly time
intervals. One study of 13 asphyxiated newborns reported
uNGAL and KIM-1 levels on days 1 and 3 of life [27].
Notably, uNGAL levels in that study were increased but
Figure 5 Results of contingency analysis. Bar graphs show the results of a contingency table analysis for urinary neutrophil gelatinase-associated
lipocalin (uNGAL; cutoff value = 126 ng/ml) and kidney injury molecule-1 (KIM-1; cutoff value of 0.19 ng/ml). A total of 49 control samples were
included (non-AKI critically ill), as well as 19 from critically ill children who developed AKI within 72 hours post-admission. AKI, Acute
kidney injury.
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on the first day of life and substantially decreased there-
after [27].
In our present study, uNGAL measured within 0 to
6 hours following admission had a reasonable ability
(ROC-AUC = 0.815) to identify children meeting AKI
criteria within 48 hours [25]. The AUC for uNGAL was
in perfect line with previous reports in adults (AUCs
0.66 to 0.88, depending on the severity of AKI). The op-
timal uNGAL cutoff value found (126 ng/ml; sensitivity
of 75%, specificity of 84%) was slightly lower thanreported for adults (247 ng/ml; sensitivity of 89% and
specificity of 70% for prediction of renal failure) [40].
The discriminative ability of KIM-1, in contrast, is only
limited, because all AUC values were ≤0.73, which is
consistent with previous reports [27,39]. All in all, the
most robust NGAL results in critically ill children come
from Mishra and colleagues for children who underwent
CPB. In their study, AKI timing and etiology post-CPB
was well defined [23,25].
Concerning the time relationship between the bio-
marker levels and AKI development, uNGAL levels in
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ing RIFLE-Risk level for the first time, whereas KIM-1
levels preceding AKI remained steady. A similar pattern
for uNGAL levels was reported in a study of adults,
but KIM-1 levels in that study did not rise until the
time AKI was diagnosed [39]. Zappitelli and col-
leagues evaluated uNGAL levels relative to the day of
pediatric RIFLE AKI attainment in 21 PICU patients
[28]. Although they presented NGAL levels relative
to urinary creatinine concentrations, it was clear that
median NGAL levels peaked at 1 day before AKI on-
set [28]. Blood was sampled daily, however, instead
of at hourly intervals.
The false-positive results of uNGAL (14%) and KIM-1
(22%) in the present study may be due to the limited
specificity of both biomarkers, but one can also specu-
late that subclinical AKI occurred, a condition in which
there is tubular damage without a rise in SCr as a sign
of glomerular filtration alteration [10]. Still, uNGAL was
able to predict AKI development correctly in 16 of 19
children, which further demonstrates its potential as an
early marker of tubular damage. Identifying children in
an early stage of AKI (for example, already at presenta-
tion in the emergency room or during clinical deterior-
ation at the general ward) may help develop early
interventions to limit the development of AKI. In this
light, several studies have been published on potential
protective properties of drugs against the development
of AKI, including atrial natriuretic factor, such as in the
cases of cisplatin treatment [41] and cardiac surgery
[42], and administration of bovine-derived alkaline phos-
phatase in critically ill patients with sepsis-associated
AKI [43]. Even though the rationale behind the renopro-
tective effects remains to be fully elucidated, these stud-
ies illustrate that new options in the prevention or
limitation of the severity of AKI are currently being
investigated.
Several limitations of this study should be addressed.
First, this study has a single-center design, which may
limit the generalization of the data to other institutions.
Still, because we did not focus on diagnostic subclasses,
our cohort can be considered a representative sample of
the general PICU population younger than 1 year of age
requiring mechanical ventilation. Second, the overall
sample size was too small for multiple subgroup ana-
lyses. Besides, because we exclusively used SCr without
urinary criteria for grading AKI severity, we may have
underestimated the incidence and grade of AKI [44].
Furthermore, we were not able to collect all urine sam-
ples planned, especially not during the first hours of
admission, when an indwelling urinary catheter yet had
to be placed, when the urine portion was needed for
clinical purposes (for example screening for metabolic
diseases) or when a patient was anuric. Still, 86% ofall planned samples were collected. Last, uNGAL and
KIM-1 levels preceding AKI could be analyzed in only a
small sample because most AKI patients already met
RIFLE-Risk criteria or higher upon admission.
Conclusions
This study shows that both uNGAL and KIM-1 levels in
critically ill infants with AKI increase following ICU ad-
mission and peak 6 to 12 hours and 12 to 24 hours
thereafter, respectively. Notably, of the children who met
AKI criteria within 48 hours following admission, almost
70% already had AKI upon admission to the ICU. Still,
uNGAL reliably discriminated between infants who met
AKI criteria within 48 hours following admission and
those who did not. In addition, uNGAL was able to pre-
dict AKI development correctly in 84% of children be-
fore any rise in SCr became apparent. These findings
support the emerging role of uNGAL in identifying AKI
at an early stage, which may in the future help us to es-
tablish timely renoprotective interventions to reduce
AKI in the most vulnerable patients in hospital.
Key messages
 Approximately 70% of the children who develop
AKI within 48 hours of admission already have AKI
when entering the ICU.
 In children with AKI, there was a temporal pattern
of increase in uNGAL and KIM-1 levels as they
peaked between 6 to 12 hours and 12 to 24 hours,
respectively, following admission.
 uNGAL concentrations at admission seems to be a
reliable marker for identifying children who will
develop AKI within 48 hours following admission.
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